<DOC>
	<DOCNO>NCT02745912</DOCNO>
	<brief_summary>The purpose study determine effect multiple oral dos naltrexone/bupropion pharmacokinetics ( PK ) single oral dose metformin .</brief_summary>
	<brief_title>Study Evaluate Effect Naltrexone Bupropion Combination Pharmacokinetics Metformin Healthy Participants</brief_title>
	<detailed_description>The drug test study naltrexone HCl bupropion HCl Extended- Release fix dose combination ( NB ) . This study evaluate potential effect multiple oral dos extended-release combination naltrexone/bupropion PK single oral dose metformin healthy participant normal renal function ( defined creatinine clearance [ CrCl ] great equal [ &gt; = ] 90 milliliter per minute [ mL/min ] /1.73 meter square [ m^2 ] ) . The study enroll approximately 30 participant . Participants receive : Metformin 850 mg single dose alone combination multiple dose Naltrexone/Bupropion Naltrexone 8 mg/Bupropion 90 mg + Naltrexone 16 mg/Bupropion 180 mg multiple dose alone combination single dose metformin All participants ask take 1 tablet metformin morning Day 1 Day 14 , 1 tablet naltrexone/bupropion twice daily Day 3 Day 5 , 2 tablet naltrexone/bupropion twice daily Day 6 Day 15 . This single center trial conduct United States . The overall time participate study 73 day . Participants admit Day -1 ( check ) remain confined clinic Day 16 contact telephone 30 ( Â±2 ) day last dose study drug follow-up assessment . Serial blood sample collect PK assessment . Safety monitor throughout study .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Bupropion hydrochloride , naltrexone hydrochoride drug combination</mesh_term>
	<criteria>1 . Is healthy male female . 2 . Is age 18 55 year , inclusive , sign informed consent first dose study drug . 3 . Weighs least 50 kilogram ( kg ) body mass index ( BMI ) 18.0 40.0 kilogram per square meter ( kg/m^2 ) , inclusive , Screening . 4 . Has normal renal function ( define CrCl &gt; =90 mL/min/1.73 m^2 ) Screening Checkin ( Day 1 ) . 5 . A female subject childbearing potential* sexually active nonsterilized* male partner agree use adequate contraception* signing inform consent throughout duration study 12 week last dose study drug . 1 . Has know hypersensitivity metformin , bupropion , naltrexone , component formulation . 2 . Has history seizure etiology , predisposition seizure . 3 . Has history bulimia . 4 . Has history anorexia nervosa . 5 . Has rest heart rate outside normal range 45 100 beat per minute Screening Checkin ( Day 1 ) confirm repeat measurement approximately 30 minute follow initial measurement . 6 . Has orthostatic blood pressure &gt; =25 millimeter mercury ( mm Hg ) Screening Checkin ( Day 1 ) confirm repeat measurement approximately 30 minute follow initial measurement . 7 . Has sustain supine systolic blood pressure &gt; =140 mm Hg less equal ( &lt; = ) 90 mm Hg diastolic blood pressure &gt; =90 mm Hg &lt; =50 mm Hg Screening Checkin ( Day 1 ) confirm repeat measurement approximately 30 minute follow initial measurement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>